# US 2026/0055146 A1 · Delivery of heterologous proteins

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2026/0055146 A1
- Document ID: US20260055146A1
- Status: Published application
- Kind: A1
- Application number: 19/105,428
- Filed: 2023-08-23
- Published: 2026-02-26
- Earliest claimed: 2022-08-24
- Assignees: Sana Biotechnology, Inc.
- Applicants: Sana Biotechnology, Inc.
- Inventors: Michael J. VOLLES; Jillian DIERX; Philip CALAFATI
- Web page: https://patentgrep.com/patent/US20260055146A1

## CPC

- C07K 14/162: {env, e.g. gp160, gp110/120, gp41, V3, peptid T, CD4-Binding site}
- C12N 15/86: Viral vectors
- C07K 14/005: from viruses
- C07K 14/161: {gag-pol, e.g. p55, p24/25, p17/18, p7, p6, p66/68, p51/52, p31/34, p32, p40}
- C07K 14/163: {Regulatory proteins, e.g. tat, nef, rev, vif, vpu, vpr, vpt, vpx}
- C12N 5/0602: {Vertebrate cells}
- C12N 15/62: DNA sequences coding for fusion proteins
- C12N 15/867: Retroviral vectors
- C12N 15/88: using microencapsulation, e.g. using {amphiphile} liposome vesicle
- C07K 2319/03: containing a transmembrane segment
- C12N 2740/16022: New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
- C12N 2740/16023: Virus like particles [VLP]
- C12N 2740/16043: viral genome or elements thereof as genetic vector
- C12N 2740/16045: Special targeting system for viral vectors
- C12N 2760/18222: New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
- C12N 2760/20222: New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
- C12N 2795/10322: New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
- C12N 2795/18122: New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
- C12N 2810/50: Vectors comprising as targeting moiety peptide derived from defined protein
- C12N 2810/6072: negative strand RNA viruses
- C12N 2810/6081: rhabdoviridae, e.g. VSV
- C12N 2840/44: being a specific part of the splice mechanism, e.g. donor, acceptor
- C07K: PEPTIDES (peptides in foodstuffs A23; obtaining protein compositions for foodstuffs, working-up proteins for foodstuffs A23J; preparations for medicinal purposes A61K; peptides containing beta-lactam rings C07D; cyclic dipeptides not having in their molecule any other peptide link than those which form their ring, e.g. piperazine-2,5-diones, C07D; ergot alkaloids of the cyclic peptide type C07D519/02; macromolecular compounds having statistically distributed amino acid units in their molecules, i.e. when the preparation does not provide for a specific; but for a random sequence of the amino acid units, homopolyamides and block copolyamides derived from amino acids C08G69/00; macromolecular products derived from proteins C08H1/00; preparation of glue or gelatine C09H; single cell proteins, enzymes C12N; genetic engineering processes for obtaining peptides C12N15/00; compositions for measuring or testing processes involving enzymes C12Q; investigation or analysis of biological material G01N33/00)
- C12N: MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA (microbiological testing media C12Q1/00)

## Abstract

Provided herein are lipid particles and compositions thereof for delivery of heterologous proteins, including genome-modifying agents, to cells.

## Claims

### Claim 1

A lipid particle comprising a lipid bilayer enclosing a lumen and a ribonucleic acid (RNA), wherein the RNA comprises, from 5′ to 3′: a R element of a 5′ long terminal repeat (5′ LTR); a U5 element of a 5′ LTR; a RNA sequence encoding a gag protein or portion thereof comprising at least a gag start codon; a RNA sequence encoding a heterologous protein that is operably linked to the RNA sequence encoding a gag protein or portion thereof; and a poly-A tail,
wherein each of the R element of the 5′ LTR, the U5 element of the 5′ LTR, and the RNA sequence encoding a gag protein or portion thereof is retroviral.

### Claim 2

A lipid particle comprising a lipid bilayer enclosing a lumen and a ribonucleic acid (RNA), wherein the RNA comprises, from 5′ to 3′: a R element of a 5′ long terminal repeat (5′ LTR); a U5 element of a 5′ LTR; a gag 5′ untranslated region (UTR) or portion thereof comprising at least three nucleotides; a RNA sequence encoding a heterologous protein that is operably linked to the gag 5′ UTR or a portion thereof; and a poly-A tail,
wherein each of the R element of the 5′ LTR, the U5 element of the 5′ LTR, and the gag 5′ UTR or portion thereof is retroviral.

### Claim 3 (depends on 1, 2)

The lipid particle of claim 1 or claim 2, wherein the RNA comprises a retroviral packaging sequence that is 3′ to the 5′ LTR.

### Claim 4

A lipid particle comprising a lipid bilayer enclosing a lumen and a ribonucleic acid (RNA), wherein the RNA comprises, from 5′ to 3′: a R element of a 5′ long terminal repeat (5′ LTR); a U5 element of a 5′ LTR; a retroviral packaging sequence; a gag start codon; a RNA sequence encoding a heterologous protein; and a poly-A tail,
wherein each of the R element of the 5′ LTR, the U5 element of the 5′ LTR, and the gag start codon is retroviral.

### Claim 5 (depends on 1, 2, 3, 4)

The lipid particle of any of claims 1-4, further comprising a U3 element of a 5′ LTR.

### Claim 6 (depends on 1, 2, 3, 4, 5)

The lipid particle of any of claims 1-5, wherein the RNA comprises a polyadenylation site.

### Claim 7 (depends on 6)

The lipid particle of claim 6, wherein the RNA comprises a 3′ long terminal repeat (3′ LTR), and the polyadenylation site is located within the 3′ LTR.

### Claim 8 (depends on 1, 2, 3, 4, 5, 6, 7)

The lipid particle of any of claims 1-7, wherein the RNA comprises a mutated primer binding site (PBS).

### Claim 9 (depends on 3, 4, 5, 6, 7, 8)

The lipid particle of any of claims 3-8, wherein the retroviral packaging sequence is selected from the group comprising HIV psi, MLV psi, SNV E, or a portion of any thereof.

### Claim 10 (depends on 3, 4, 5, 6, 7, 8, 9)

The lipid particle of any of claims 3-9, wherein the retroviral packaging sequence comprises stem-loop 1 (SL1) of HIV psi.

### Claim 11 (depends on 3, 4, 5, 6, 7, 8, 9, 10)

The lipid particle of any of claims 3-10, wherein the retroviral packaging sequence comprises stem-loop 2 (SL2) of HIV psi.

### Claim 12 (depends on 3, 4, 5, 6, 7, 8, 9, 10, 11)

The lipid particle of any of claims 3-11, wherein the retroviral packaging sequence comprises stem-loop 3 (SL3) of HIV psi.

### Claim 13 (depends on 3, 4, 5, 6, 7, 8, 9, 10, 11, 12)

The lipid particle of any of claims 3-12, wherein the retroviral packaging sequence comprises stem-loop 4 (SL4) of HIV psi.

### Claim 14 (depends on 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13)

The lipid particle of any one of claims 3-13, wherein the retroviral packaging sequence is HIV psi.

### Claim 15 (depends on 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14)

The lipid particle of any one of claims 3-14, wherein the retroviral packaging sequence comprises a mutation in a major splice donor site.

### Claim 16 (depends on 15)

The lipid particle of claim 15, wherein the major splice donor site is a major splice donor site contained in SL2 of HIV psi.

### Claim 17 (depends on 15, 16)

The lipid particle of claim 15 or claim 16, wherein the mutation is a mutation that inhibits splicing at the major splice donor site.

### Claim 18 (depends on 15, 16, 17)

The lipid particle of any one of claims 15-17, wherein the mutation in the major splice donor site comprises a mutation that prevents splicing at the major splice donor site.

### Claim 19 (depends on 1, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18)

The lipid particle of any of claims 1 and 3-18, wherein the RNA comprises a retroviral sequence having at least about 80% sequence identity to the sequence of a retroviral genome that is about 20, 30, 40, 50, 60, 70, 80, 90, 100, 120, 140, 160, 180, 200, 220, 240, 260, 280, 300, 320, 340, 360, 380, or 400 nucleotides in length and comprises the gag start codon.

### Claim 20 (depends on 2, 3)

The lipid particle of any of claims 2, 3, and 5-18, wherein the RNA comprises a retroviral sequence having at least about 80% sequence identity to the sequence of a retroviral genome that is about 20, 30, 40, 50, 60, 70, 80, 90, 100, 120, 140, 160, 180, 200, 220, 240, 260, 280, 300, 320, 340, 360, 380, or 400 nucleotides in length and comprises a gag start codon.

### Claim 21 (depends on 19, 20)

The lipid particle of claim 19 or claim 20, wherein the retroviral sequence comprises between about 20-400, between about 40 and about 350, between about 60 and about 300, between about 80 and about 250, or between about 100 and about 200 nucleotides 5′ to the gag start codon.

### Claim 22 (depends on 19, 20, 21)

The lipid particle of any of claims 19-21, wherein the retroviral sequence comprises between about 20 and about 400, between about 40 and about 350, between about 60 and about 300, between about 80 and about 250, or between about 100 and about 200 nucleotides 3′ to the gag start codon.

### Claim 23 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22)

The lipid particle of any of claims 1-22, wherein the lumen comprises a capsid comprising a retroviral capsid protein enclosing the RNA.

### Claim 24 (depends on 23)

The lipid particle of claim 23, wherein the retroviral capsid protein and the retroviral packaging sequence are capable of associating with each other, optionally wherein the retroviral capsid protein and the retroviral packaging sequence are from the same retroviral species.

### Claim 25 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24)

The lipid particle of any of claims 1-24, wherein the lipid particle comprises a retroviral matrix protein.

### Claim 26 (depends on 1, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25)

The lipid particle of any of claims 1 and 3-25, further comprising a RNA sequence encoding a viral structural protein or a portion thereof, which is located between the gag start codon and the RNA sequence encoding a heterologous protein.

### Claim 27 (depends on 1, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25)

The lipid particle of any of claims 1 and 3-25, wherein the RNA does not comprise nucleotides between the gag start codon and the RNA sequence encoding a heterologous protein.

### Claim 28

A lipid particle comprising a lipid bilayer enclosing a lumen and a ribonucleic acid (RNA), wherein the RNA comprises, from 5′ to 3′: a R element of a 5′ long terminal repeat (5′ LTR); a U5 element of a 5′ LTR; a RNA sequence encoding a viral structural protein or a portion thereof; a RNA sequence encoding a heterologous protein; and a poly-A tail,
wherein each of the R element of the 5′ LTR and the U5 element of the 5′ LTR is retroviral.

### Claim 29 (depends on 28)

The lipid particle of claim 28, wherein the viral structural protein or a portion thereof is a retroviral structural protein or a portion thereof.

### Claim 30 (depends on 26, 28)

The lipid particle of any of claims 26, 28, and 29, wherein the RNA comprises a bicistronic element located between the RNA sequence encoding the viral structural protein or a portion thereof and the RNA sequence encoding the heterologous protein.

### Claim 31 (depends on 30)

The lipid particle of claim 30, wherein the bicistronic element is an internal ribosome entry site (IRES) element or a sequence encoding a 2A self-cleaving peptide.

### Claim 32 (depends on 30, 31)

The lipid particle of claim 30 or claim 31, wherein the bicistronic element is a sequence encoding a 2A self-cleaving peptide, and the 2A self-cleaving peptide is T2A.

### Claim 33 (depends on 32)

The lipid particle of claim 32, wherein T2A comprises the sequence set forth in SEQ ID NO: 76.

### Claim 34 (depends on 25, 27, 28, 29, 30, 31, 32, 33)

The lipid particle of any of claims 25 and 27-33, wherein the RNA encodes, from a 5′ to 3′ direction: the viral structural protein or portion thereof, T2A, and the heterologous protein.

### Claim 35 (depends on 26, 28, 29, 30, 31, 32, 33, 34)

The lipid particle of any of claims 26 and 28-34, wherein the viral structural protein is a retroviral gag.

### Claim 36 (depends on 35)

The lipid particle of claim 35, wherein the RNA sequence encoding the viral structural protein or a portion thereof encodes an N-terminal portion of a retroviral gag.

### Claim 37 (depends on 35, 36)

The lipid particle of claim 35 or claim 36, wherein the RNA sequence encoding the viral structural protein or a portion thereof comprises the sequence set forth in SEQ ID NO:52.

### Claim 38 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37)

The lipid particle of any of claims 1-37, wherein the RNA encodes the sequence set forth in SEQ ID NO:77 and the heterologous protein.

### Claim 39 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38)

The lipid particle of any of claims 1-38, wherein the RNA is present as a first genomic viral RNA and the lipid particle further comprises a second genomic viral RNA.

### Claim 40 (depends on 39)

The lipid particle of claim 39, wherein the first genomic viral RNA and the second viral genomic RNA genome are identical.

### Claim 41 (depends on 39)

The lipid particle of claim 39, wherein the first genomic viral RNA and the second viral genomic RNA genome are different.

### Claim 42 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41)

The lipid particle of any of claims 1-41, wherein the heterologous protein is a first heterologous protein and the lipid particle further comprises one or more additional heterologous protein(s), wherein the lipid particle comprises:
(a) a viral matrix (MA) protein, a MS2 coat protein (MS2cp), and an RNA sequence encoding the one or more additional heterologous protein(s), wherein the MS2cp is incorporated into the lipid particle as a fusion protein with the viral MA protein, and wherein the RNA sequence encoding the one or more additional heterologous protein(s) comprises a MS2cp-binding loop for binding to MS2cp; and/or
(b) a fusion protein comprising a viral matrix (MA) protein and the one or more additional heterologous protein(s).

### Claim 43 (depends on 42)

The lipid particle of claim 42, wherein the viral MA protein in (a) and/or (b) is derived from human immunodeficiency virus (HIV).

### Claim 44 (depends on 42, 43)

The lipid particle of claim 42 or claim 43, wherein the viral MA protein in (a) and/or (b) comprises the sequence set forth in SEQ ID NO:78.

### Claim 45 (depends on 42, 43, 44)

The lipid particle of any of claims 42-44, wherein MS2cp in (a) comprises the sequence set forth in SEQ ID NO:79.

### Claim 46 (depends on 42, 43, 44, 45)

The lipid particle of any of claims 42-45, wherein the fusion protein of (a) comprises the sequence set forth in SEQ ID NO:74.

### Claim 47 (depends on 42, 43, 44, 45)

The lipid particle of any one of claims 42-45, wherein the fusion protein of (a) comprises:
the amino acid sequence of SEQ ID NOs: 134 or 190; or
the amino acid sequence of SEQ ID NOs: 74 or 191; or
the amino acid sequence encoded by the nucleic acid sequence set forth in SEQ ID NO: 62 or 150.

### Claim 48 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44, 45, 46, 47)

The lipid particle of any of claims 1-47, wherein the RNA comprises a 5′ cap.

### Claim 49 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44, 45, 46, 47, 48)

The lipid particle of any of claims 1-48, wherein the RNA is a self-inactivating lentiviral vector genome.

### Claim 50

A lipid particle comprising a lipid bilayer enclosing a lumen; a fusion protein comprising a viral matrix (MA) protein and a MS2 coat protein (MS2cp); and an RNA sequence encoding a heterologous protein.

### Claim 51 (depends on 50)

The lipid particle of claim 50, wherein the RNA sequence encoding a heterologous protein comprises a MS2cp-binding loop.

### Claim 52 (depends on 51)

The lipid particle of claim 51, wherein the MS2cp-binding loop comprises the RNA sequence transcribed from the nucleic acid set forth in SEQ ID NO: 185 or SEQ ID NO: 174.

### Claim 53 (depends on 51, 52)

The lipid particle of claim 51 or claim 52, wherein the MS2cp-binding loop comprises the RNA sequence set forth in SEQ ID NO: 208.

### Claim 54 (depends on 50, 51, 52, 53)

The lipid particle of any one of claims 50-53, wherein the RNA sequence encoding a heterologous protein comprises a plurality of MS2cp-binding loops.

### Claim 55 (depends on 54)

The lipid particle of claim 54, wherein the plurality of MS2cp-binding loops comprises at or a at least 2, 5, 6, 10, 12, 15, 20, or 24 MS2cp-binding loops.

### Claim 56 (depends on 50, 51, 52, 53, 54, 55)

The lipid particle of any one of claims 50-55, wherein the RNA sequence encoding a heterologous protein comprises a plurality of MS2cp-binding loops comprising between or between about 1 and 50, 1 and 40, 1 and 30, 1 and 25, 1 and 20, 2 and 50, 2 and 40, 2 and 30, 2 and 25, 2 and 20, 4 and 50, 4 and 40, 4 and 30, 4 and 25, 4 and 20, 5 and 50, 5 and 40, 5 and 30, 5 and 25, 5 and 20, 6 and 50, 6 and 40, 6 and 30, 6 and 25, 6 and 20, 10 and 50, 10 and 40, 10 and 30, 10 and 25, 10 and 20, 12 and 50, 12 and 40, 12 and 30, 12 and 25, 12 and 20, 15 and 50, 15 and 40, 15 and 30, 15 and 25, or 15 and 20 MS2cp-binding loops.

### Claim 57 (depends on 54, 55, 56)

The lipid particle of any one of claims 54-56, wherein the plurality of MS2cp-binding loops comprises the RNA sequence transcribed from a nucleic acid sequence selected from the group consisting of SEQ ID NOs: 175-178.

### Claim 58

A lipid particle comprising a lipid bilayer enclosing a lumen; a viral matrix (MA) protein; an RNA-binding protein; and an RNA sequence encoding a heterologous protein, wherein the RNA-binding protein is incorporated into the lipid particle as a fusion protein with the viral MA protein, and wherein the RNA sequence encoding the heterologous protein comprises a binding site for binding to the RNA-binding protein.

### Claim 59 (depends on 58)

The lipid particle of claim 58, wherein the RNA sequence encoding a heterologous protein comprises at or at least 2, 5, 6, 10, 12, 15, 20, or 24 binding sites for binding to the RNA-binding protein.

### Claim 60 (depends on 58, 59)

The lipid particle of claim 58 or claim 59, wherein the RNA sequence encoding a heterologous protein comprises between or between about 1 and 50, 1 and 40, 1 and 30, 1 and 25, 1 and 20, 2 and 50, 2 and 40, 2 and 30, 2 and 25, 2 and 20, 4 and 50, 4 and 40, 4 and 30, 4 and 25, 4 and 20, 5 and 50, 5 and 40, 5 and 30, 5 and 25, 5 and 20, 6 and 50, 6 and 40, 6 and 30, 6 and 25, 6 and 20, 10 and 50, 10 and 40, 10 and 30, 10 and 25, 10 and 20, 12 and 50, 12 and 40, 12 and 30, 12 and 25, 12 and 20, 15 and 50, 15 and 40, 15 and 30, 15 and 25, or 15 and 20, binding sites for binding to the RNA-binding protein.

### Claim 61 (depends on 58, 59, 60)

The lipid particle of any one of claims 58-60, wherein the RNA-binding protein is MS2 coat protein (MS2cp).

### Claim 62 (depends on 61)

The lipid particle of claim 61, wherein MS2cp comprises the sequence set forth in SEQ ID NO: 79.

### Claim 63 (depends on 58, 59, 60, 61, 62)

The lipid particle of any one of claims 58-62, wherein the RNA-binding protein is MS2cp and the binding site is an MS2cp-binding loop for binding to the MS2cp.

### Claim 64 (depends on 63)

The lipid particle of claim 63, wherein the MS2cp-binding loop comprises the RNA sequence transcribed from the nucleic acid set forth in SEQ ID NO: 185 or SEQ ID NO: 174.

### Claim 65 (depends on 63, 64)

The lipid particle of claim 63 or claim 64, wherein the MS2cp-binding loop comprises the RNA sequence set forth in SEQ ID NO: 208.

### Claim 66 (depends on 58, 59, 60, 61, 62, 63, 64, 65)

The lipid particle of any one of claims 58-65, wherein the RNA sequence encoding a heterologous protein comprises a plurality of MS2cp-binding loops.

### Claim 67 (depends on 66)

The lipid particle of claim 66, wherein the plurality of MS2cp-binding loops comprises between or between about 1 and 50, 1 and 40, 1 and 30, 1 and 25, 1 and 20, 2 and 50, 2 and 40, 2 and 30, 2 and 25, 2 and 20, 4 and 50, 4 and 40, 4 and 30, 4 and 25, 4 and 20, 5 and 50, 5 and 40, 5 and 30, 5 and 25, 5 and 20, 6 and 50, 6 and 40, 6 and 30, 6 and 25, 6 and 20, 10 and 50, 10 and 40, 10 and 30, 10 and 25, 10 and 20, 12 and 50, 12 and 40, 12 and 30, 12 and 25, 12 and 20, 15 and 50, 15 and 40, 15 and 30, 15 and 25, or 15 and 20 MS2cp-binding loops.

### Claim 68 (depends on 66, 67)

The lipid particle of claim 66 or claim 67, wherein the plurality of MS2cp-binding loops comprises at or at least 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, or 30 MS2cp-binding loops.

### Claim 69 (depends on 66, 67, 68)

The lipid particle of any one of claims 66-68, wherein the plurality of MS2cp-binding loops comprises the RNA sequence transcribed from a nucleic acid sequence selected from the group consisting of SEQ ID NOs: 175-178.

### Claim 70 (depends on 58, 59, 60)

The lipid particle of any one of claims 58-60, wherein the RNA-binding protein is lambda N protein (λN) or a functional variant thereof.

### Claim 71 (depends on 70)

The lipid particle of claim 70, wherein the λN or a functional variant thereof comprises the amino acid sequence of SEQ ID NO: 187 or an amino acid sequence having at least 90% or 95% sequence identity to the amino acid sequence of SEQ ID NO: 187.

### Claim 72 (depends on 70, 71)

The lipid particle of claim 70 or claim 71, wherein the λN or a functional variant thereof comprises the amino acid sequence of SEQ ID NO: 187.

### Claim 73 (depends on 70)

The lipid particle of claim 70, wherein the λN or a functional variant thereof comprises the amino acid sequence of SEQ ID NO: 188 or an amino acid sequence having at least 90% or 95% sequence identity to the amino acid sequence of SEQ ID NO: 188.

### Claim 74 (depends on 70, 73)

The lipid particle of claim 70 or claim 73, wherein the λN or a functional variant thereof comprises the amino acid sequence of SEQ ID NO: 188.

### Claim 75 (depends on 58, 59, 60, 70, 71, 72, 73, 74)

The lipid particle of any one of claims 58-60 and 70-74, wherein the RNA-binding protein is λN or a functional variant thereof and the binding site is a boxB binding site for binding to the λN or a functional variant thereof.

### Claim 76 (depends on 75)

The lipid particle of claim 75, wherein the boxB binding site comprises the RNA sequence transcribed from the nucleic acid set forth in SEQ ID NO: 186.

### Claim 77 (depends on 58, 59, 60, 70, 71, 72, 73, 74, 75, 76)

The lipid particle of any one of claims 58-60 and 70-76, wherein the RNA sequence encoding a heterologous protein comprises a plurality of boxB binding sites.

### Claim 78

The lipid particle of 77, wherein the plurality of boxB binding sites comprises between or between about 1 and 50, 1 and 40, 1 and 30, 1 and 25, 1 and 20, 2 and 50, 2 and 40, 2 and 30, 2 and 25, 2 and 20, 4 and 50, 4 and 40, 4 and 30, 4 and 25, 4 and 20, 5 and 50, 5 and 40, 5 and 30, 5 and 25, 5 and 20, 6 and 50, 6 and 40, 6 and 30, 6 and 25, 6 and 20, 10 and 50, 10 and 40, 10 and 30, 10 and 25, 10 and 20, 12 and 50, 12 and 40, 12 and 30, 12 and 25, 12 and 20, 15 and 50, 15 and 40, 15 and 30, 15 and 25, or 15 and 20 boxB binding sites.

### Claim 79 (depends on 77, 78)

The lipid particle of claim 77 or claim 78, wherein the plurality of boxB binding sites comprises at or at least 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, or 30 boxB binding sites.

### Claim 80 (depends on 77, 78, 79)

The lipid particle of any one of claims 77-79, wherein the plurality of boxB binding sites comprises the RNA sequence transcribed from a nucleic acid sequence selected from the group consisting of SEQ ID NOs: 179-184.

### Claim 81

A lipid particle comprising a lipid bilayer enclosing a lumen; a viral matrix (MA) protein; a MS2 coat protein (MS2cp); and an RNA sequence encoding a heterologous protein, wherein the MS2cp is incorporated into the lipid particle as a fusion protein with the viral MA protein, and wherein the RNA sequence encoding the heterologous protein comprises a MS2cp-binding loop for binding to MS2cp.

### Claim 82 (depends on 50, 51, 52, 53, 54, 55, 56, 57, 58, 59, 60, 61, 62, 63, 64, 65, 66, 67, 68, 69, 70, 71, 72, 73, 74, 75, 76, 77, 78, 79, 80, 81)

The lipid particle of any of claims 50-81, wherein the viral MA protein is attached to a portion of the lipid bilayer that is in contact with the lumen.

### Claim 83 (depends on 50, 51, 52, 53, 54, 55, 56, 57, 58, 59, 60, 61, 62, 63, 64, 65, 66, 67, 68, 69, 70, 71, 72, 73, 74, 75, 76, 77, 78, 79, 80, 81, 82)

The lipid particle of any of claims 50-82, wherein the viral MA protein reversibly binds to the lipid bilayer.

### Claim 84 (depends on 50, 51, 52, 53, 54, 55, 56, 57, 58, 59, 60, 61, 62, 63, 64, 65, 66, 67, 68, 69, 70, 71, 72, 73, 74, 75, 76, 77, 78, 79, 80, 81, 82, 83)

The lipid particle of any of claims 50-83, wherein the fusion protein comprises, from a 5′ to 3′ direction: the viral MA protein and MS2cp.

### Claim 85 (depends on 50, 51, 52, 53, 54, 55, 56, 57, 58, 59, 60, 61, 62, 63, 64, 65, 66, 67, 68, 69, 70, 71, 72, 73, 74, 75, 76, 77, 78, 79, 80, 81, 82, 83, 84)

The lipid particle of any of claims 50-84, wherein the RNA sequence encoding a heterologous protein comprises a MS2cp-binding loop, optionally 12 or 24 MS2cp-binding loops.

### Claim 86 (depends on 50, 51, 52, 53, 54, 55, 56, 57, 58, 59, 60, 61, 62, 63, 64, 65, 66, 67, 68, 69, 70, 71, 72, 73, 74, 75, 76, 77, 78, 79, 80, 81, 82, 83, 84, 85)

The lipid particle of any of claims 50-85, wherein the viral MA protein is derived from human immunodeficiency virus (HIV).

### Claim 87 (depends on 50, 51, 52, 53, 54, 55, 56, 57, 58, 59, 60, 61, 62, 63, 64, 65, 66, 67, 68, 69, 70, 71, 72, 73, 74, 75, 76, 77, 78, 79, 80, 81, 82, 83, 84, 85, 86)

The lipid particle of any of claims 50-86, wherein the viral MA protein comprises the sequence set forth in SEQ ID NO:78.

### Claim 88 (depends on 50, 51, 52, 53, 54, 55, 56, 57, 58, 59, 60, 61, 62, 63, 64, 65, 66, 67, 68, 69, 70, 71, 72, 73, 74, 75, 76, 77, 78, 79, 80, 81, 82, 83, 84, 85, 86, 87)

The lipid particle of any of claims 50-87, wherein MS2cp comprises the sequence set forth in SEQ ID NO:79.

### Claim 89 (depends on 50, 51, 52, 53, 54, 55, 56, 57, 58, 59, 60, 61, 62, 63, 64, 65, 66, 67, 68, 69, 70, 71, 72, 73, 74, 75, 76, 77, 78, 79, 80, 81, 82, 83, 84, 85, 86, 87, 88)

The lipid particle of any of claims 50-88, wherein the fusion protein comprises the sequence set forth in SEQ ID NO:74.

### Claim 90 (depends on 50, 51, 52, 53, 54, 55, 56, 57, 58, 59, 60, 61, 62, 63, 64, 65, 66, 67, 68, 69, 70, 71, 72, 73, 74, 75, 76, 77, 78, 79, 80, 81, 82, 83, 84, 85, 86, 87, 88, 89)

The lipid particle of any of claims 50-89, further comprising a transfer plasmid encoding a guide RNA (gRNA), optionally a single guide RNA (sgRNA), under the control of a U6 promoter.

### Claim 91 (depends on 50, 51, 52, 53, 54, 55, 56, 57, 58, 59, 60, 61, 62, 63, 64, 65, 66, 67, 68, 69, 70, 71, 72, 73, 74, 75, 76, 77, 78, 79, 80, 81, 82, 83, 84, 85, 86, 87, 88, 89, 90)

The lipid particle of any of claims 50-90, wherein the heterologous protein is a first heterologous protein and the lipid particle further comprises one or more additional heterologous protein(s), wherein the lipid particle comprises:
(a) a RNA comprising a RNA sequence encoding the one or more additional heterologous protein(s) and a RNA sequence encoding a viral structural protein or a portion thereof; and/or
(b) a fusion protein comprising a viral matrix (MA) protein and the one or more additional heterologous protein(s).

### Claim 92 (depends on 91)

The lipid particle of claim 91, wherein the viral structural protein is gag.

### Claim 93 (depends on 92)

The lipid particle of claim 92, wherein the RNA sequence encoding the viral structural protein or a portion thereof in (a) encodes an N-terminal portion of gag.

### Claim 94 (depends on 92, 93)

The lipid particle of claim 92 or claim 93, wherein the RNA sequence encoding the viral structural protein or a portion thereof in (a) comprises the sequence set forth in SEQ ID NO:52.

### Claim 95 (depends on 92, 93, 94)

The lipid particle of any of claims 92-94, wherein the viral MA protein in (b) is derived from human immunodeficiency virus (HIV).

### Claim 96 (depends on 92, 93, 94, 95)

The lipid particle of any of claims 92-95, wherein the viral MA protein in (b) comprises the sequence set forth in SEQ ID NO:78.

### Claim 97

A lipid particle comprising a lipid bilayer enclosing a lumen a fusion protein comprising a viral matrix (MA) protein and a heterologous protein.

### Claim 98

A lipid particle comprising a lipid bilayer enclosing a lumen; a viral matrix (MA) protein; and a heterologous protein, wherein the heterologous protein is incorporated into the lipid particle as a fusion protein with the viral MA protein.

### Claim 99 (depends on 97, 98)

The lipid particle of claim 97 or claim 98, wherein the viral MA protein is attached to a portion of the lipid bilayer that is in contact with the lumen.

### Claim 100 (depends on 97, 98, 99)

The lipid particle of any of claims 97-99, wherein the viral MA protein reversibly binds to the lipid bilayer.

### Claim 101 (depends on 97, 98, 99, 100)

The lipid particle of any of claims 97-100, wherein the fusion protein comprises, from a 5′ to 3′ direction: the viral MA protein and the heterologous protein.

### Claim 102 (depends on 97, 98, 99, 100, 101)

The lipid particle of any of claims 97-101, wherein the viral MA protein is derived from human immunodeficiency virus (HIV).

### Claim 103 (depends on 97, 98, 99, 100, 101, 102)

The lipid particle of any of claims 97-102, wherein the viral MA protein comprises the sequence set forth in SEQ ID NO:78.

### Claim 104 (depends on 97, 98, 99, 100, 101, 102, 103)

The lipid particle of any of claims 97-103, further comprising a transfer plasmid encoding a guide RNA (gRNA), optionally a single guide RNA (sgRNA), under the control of a U6 promoter.

### Claim 105 (depends on 97, 98, 99, 100, 101, 102, 103, 104)

The lipid particle of any of claims 97-104, wherein the heterologous protein is a first heterologous protein and the lipid particle further comprises one or more additional heterologous protein(s), wherein the lipid particle comprises:
(a) a RNA comprising a RNA sequence encoding the one or more additional heterologous protein(s) and a RNA sequence encoding a viral structural protein or a portion thereof; and/or
(b) a viral matrix (MA) protein, a MS2 coat protein (MS2cp), and a RNA sequence encoding the one or more additional heterologous protein(s), wherein the MS2cp is incorporated into the lipid particle as a fusion protein with the viral MA protein, and wherein the RNA sequence encoding the one or more additional heterologous protein(s) comprises a MS2cp-binding loop for binding to MS2cp.

### Claim 106 (depends on 105)

The lipid particle of claim 105, wherein the viral structural protein in (a) is gag.

### Claim 107 (depends on 106)

The lipid particle of claim 106, wherein the RNA sequence encoding the viral structural protein or a portion thereof in (a) encodes an N-terminal portion of gag.

### Claim 108 (depends on 106, 107)

The lipid particle of claim 106 or claim 107, wherein the RNA sequence encoding the viral structural protein or a portion thereof in (a) comprises the sequence set forth in SEQ ID NO:52.

### Claim 109 (depends on 105, 106, 107, 108)

The lipid particle of any of claims 105-108, wherein the viral MA protein in (b) is derived from HIV.

### Claim 110 (depends on 105, 106, 107, 108, 109)

The lipid particle of any of claims 105-109, wherein the viral MA protein in (b) comprises the sequence set forth in SEQ ID NO:78.

### Claim 111 (depends on 105, 106, 107, 108, 109, 110)

The lipid particle of any of claims 105-110, wherein MS2cp in (b) comprises the sequence set forth in SEQ ID NO:79.

### Claim 112 (depends on 105, 106, 107, 108, 109, 110, 111)

The lipid particle of any of claims 105-111, wherein the fusion protein of (b) comprises the sequence set forth in SEQ ID NO:74.

### Claim 113 (depends on 105, 106, 107, 108, 109, 110, 111, 112)

The lipid particle of any of claims 105-112, wherein the fusion protein of (b) comprises the sequence set forth in SEQ ID NO: 191.

### Claim 114

A lipid particle comprising a lipid bilayer enclosing a lumen; a fusion protein comprising a viral envelope glycoprotein and an RNA-binding protein; and an RNA sequence encoding a heterologous protein, wherein the RNA sequence encoding the heterologous protein comprises a binding site for binding to the RNA-binding protein.

### Claim 115 (depends on 114)

The lipid particle of claim 114, wherein the fusion protein comprises, from an N-terminus to C-terminus direction: the viral envelope glycoprotein and the RNA binding protein.

### Claim 116 (depends on 114, 115)

The lipid particle of claim 114 or claim 115, wherein the RNA-binding protein is fused to the C-terminus of the viral envelope glycoprotein.

### Claim 117

A lipid particle comprising a lipid bilayer enclosing a lumen; a fusion protein comprising a VSV-G protein or a functional variant thereof and an RNA-binding protein; and an RNA sequence encoding a heterologous protein, wherein the RNA sequence encoding the heterologous protein comprises a binding site for binding to the RNA-binding protein.

### Claim 118 (depends on 117)

The lipid particle of claim 117, wherein the VSV-G or a functional variant thereof comprises the amino acid sequence of SEQ ID NO: 199, or an amino acid sequence having at least 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% sequence identity to the amino acid sequence of SEQ ID NO: 199.

### Claim 119 (depends on 117, 118)

The lipid particle of claim 117 or claim 118, wherein the VSV-G or a functional variant thereof comprises the amino acid sequence of SEQ ID NO: 199.

### Claim 120 (depends on 114, 115, 116, 117, 118, 119)

The lipid particle of any one of claims 114-119, wherein the RNA sequence encoding a heterologous protein comprises at or at least 2, 5, 6, 10, 12, 15, 20, or 24 binding sites for binding to the RNA-binding protein.

### Claim 121 (depends on 114, 115, 116, 117, 118, 119, 120)

The lipid particle of any one of claims 114-120, wherein the RNA sequence encoding a heterologous protein comprises between or between about 1 and 50, 1 and 40, 1 and 30, 1 and 25, 1 and 20, 2 and 50, 2 and 40, 2 and 30, 2 and 25, 2 and 20, 4 and 50, 4 and 40, 4 and 30, 4 and 25, 4 and 20, 5 and 50, 5 and 40, 5 and 30, 5 and 25, 5 and 20, 6 and 50, 6 and 40, 6 and 30, 6 and 25, 6 and 20, 10 and 50, 10 and 40, 10 and 30, 10 and 25, 10 and 20, 12 and 50, 12 and 40, 12 and 30, 12 and 25, 12 and 20, 15 and 50, 15 and 40, 15 and 30, 15 and 25, or 15 and 20, binding sites for binding to the RNA-binding protein.

### Claim 122 (depends on 114, 115, 116)

The lipid particle of any one of claims 114-116, wherein the lipid particle is pseudotyped with the viral envelope glycoprotein.

### Claim 123 (depends on 117, 118, 119, 120, 121)

The lipid particle of any one of claims 117-121, wherein the fusion protein comprises, from an N-terminus to C-terminus direction: the VSV-G protein or a functional variant thereof and the RNA binding protein.

### Claim 124 (depends on 117, 118, 119, 120, 121)

The lipid particle of any one of claims 117-121, wherein the RNA-binding protein is fused to the C-terminus of the VSV-G protein or a functional variant thereof.

### Claim 125 (depends on 114, 115, 116, 117, 118, 119, 120, 121, 122, 123, 124)

The lipid particle of any one of claims 114-124, wherein the RNA-binding protein is MS2 coat protein (MS2cp).

### Claim 126 (depends on 125)

The lipid particle of claim 125, wherein MS2cp comprises the sequence set forth in SEQ ID NO: 79.

### Claim 127 (depends on 125, 126)

The lipid particle of claim 125 or claim 126, wherein the MS2cp is a homodimer.

### Claim 128 (depends on 125, 126)

The lipid particle of claim 125 or claim 126, wherein the MS2cp is a tandem dimer.

### Claim 129 (depends on 114, 115, 116, 117, 118, 119, 120, 121, 122, 123, 124, 125, 126, 127, 128)

The lipid particle of any one of claims 114-128, wherein the binding site is an MS2cp-binding loop for binding to the MS2cp.

### Claim 130 (depends on 114, 115, 116, 117, 118, 119, 120, 121, 122, 123, 124, 125, 126, 127, 128, 129)

The lipid particle of any one of claims 114-129, wherein the RNA sequence encoding a heterologous protein comprises a plurality of MS2cp-binding loops for binding to the MS2cp.

### Claim 131 (depends on 130)

The lipid particle of claim 130, wherein the plurality of MS2cp-binding loops comprises at or at least 2, 4, 6, 8, 10, 12, 14, 16, 18, 20, 22, or 24 MS2cp-binding loops.

### Claim 132 (depends on 130, 131)

The lipid particle of claim 130 or claim 131, wherein the plurality of MS2cp-binding loops comprises between or between about 1 and 50, 1 and 40, 1 and 30, 1 and 25, 1 and 20, 2 and 50, 2 and 40, 2 and 30, 2 and 25, 2 and 20, 4 and 50, 4 and 40, 4 and 30, 4 and 25, 4 and 20, 5 and 50, 5 and 40, 5 and 30, 5 and 25, 5 and 20, 6 and 50, 6 and 40, 6 and 30, 6 and 25, 6 and 20, 10 and 50, 10 and 40, 10 and 30, 10 and 25, 10 and 20, 12 and 50, 12 and 40, 12 and 30, 12 and 25, 12 and 20, 15 and 50, 15 and 40, 15 and 30, 15 and 25, or 15 and 20 MS2cp-binding loops.

### Claim 133 (depends on 130, 131, 132)

The lipid particle of any one of claims 130-132, wherein the plurality of MS2cp-binding loops comprises at or at least 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, or 30 MS2cp-binding loops.

### Claim 134 (depends on 114, 115, 116, 117, 118, 119, 120, 121, 122, 123, 124)

The lipid particle of any one of claims 114-124, wherein the RNA-binding protein is lambda N protein (λN) or a functional variant thereof.

### Claim 135 (depends on 134)

The lipid particle of claim 134, wherein the λN or a functional variant thereof comprises the amino acid sequence of SEQ ID NO: 187 or an amino acid sequence having at least 90% or 95% sequence identity to the amino acid sequence of SEQ ID NO: 187.

### Claim 136 (depends on 134, 135)

The lipid particle of claim 134 or claim 135, wherein the λN or a functional variant thereof comprises the amino acid sequence of SEQ ID NO: 187.

### Claim 137 (depends on 134)

The lipid particle of claim 134, wherein the λN or a functional variant thereof comprises the amino acid sequence of SEQ ID NO: 188 or an amino acid sequence having at least 90% or 95% sequence identity to the amino acid sequence of SEQ ID NO: 188.

### Claim 138 (depends on 134)

The lipid particle of claim 134, wherein the λN or a functional variant thereof comprises the amino acid sequence of SEQ ID NO: 188.

### Claim 139 (depends on 114, 115, 116, 117, 118, 119, 120, 121, 122, 123, 124, 125, 134, 135, 136, 137, 138)

The lipid particle of any one of claims 114-125 and 134-138, wherein the RNA-binding protein is λN or a functional variant thereof and the binding site is a boxB binding site for binding to the λN or a functional variant thereof.

### Claim 140 (depends on 114, 115, 116, 117, 118, 119, 120, 121, 122, 123, 124, 134, 135, 136, 137, 138, 139)

The lipid particle of any one of claims 114-124 and 134-139, wherein the RNA sequence encoding a heterologous protein comprises a plurality of boxB binding sites.

### Claim 141 (depends on 140)

The lipid particle of any one of claim 140, wherein the plurality of boxB binding sites comprises between or between about 1 and 50, 1 and 40, 1 and 30, 1 and 25, 1 and 20, 2 and 50, 2 and 40, 2 and 30, 2 and 25, 2 and 20, 4 and 50, 4 and 40, 4 and 30, 4 and 25, 4 and 20, 5 and 50, 5 and 40, 5 and 30, 5 and 25, 5 and 20, 6 and 50, 6 and 40, 6 and 30, 6 and 25, 6 and 20, 10 and 50, 10 and 40, 10 and 30, 10 and 25, 10 and 20, 12 and 50, 12 and 40, 12 and 30, 12 and 25, 12 and 20, 15 and 50, 15 and 40, 15 and 30, 15 and 25, or 15 and 20 boxB binding sites.

### Claim 142 (depends on 140, 141)

The lipid particle of claim 140 or claim 141, wherein the plurality of MS2cp-binding loops comprises at or at least 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, or 30 MS2cp-binding loops.

### Claim 143 (depends on 140, 141, 142)

The lipid particle of any one of claims 140-142, wherein the plurality of boxB binding sites comprises the RNA sequence transcribed from a nucleic acid sequence selected from the group consisting of SEQ ID NOs: 179-184.

### Claim 144 (depends on 1, 143)

The lipid particle of any of claims 1-143, wherein the heterologous protein is a genome-modifying protein.

### Claim 145 (depends on 144)

The lipid particle of claim 144, wherein the genome-modifying protein comprises a recombinant nuclease, a nickase, an integrase, reverse transcriptase, or a combination thereof.

### Claim 146 (depends on 144, 145)

The lipid particle of claim 144 or claim 145, wherein the genome-modifying protein comprises a zinc-finger nuclease (ZFN), a transcription-activator like effector nucleases (TALEN), or a CRISPR-associated (Cas) protein.

### Claim 147 (depends on 144, 145, 146)

The lipid particle of any of claims 144-146, wherein the genome-modifying protein is a Cas protein.

### Claim 148 (depends on 144, 145, 146, 147)

The lipid particle of any of claims 144-147, wherein the genome-modifying protein is (i) Cas9, optionally saCas9 or spCas9; or (ii) cpf1.

### Claim 149 (depends on 1, 148)

The lipid particle of any of claims 1-148, further comprising a guide RNA (gRNA) in the lumen.

### Claim 150 (depends on 149)

The lipid particle of claim 149, wherein the gRNA is a single guide RNA (sgRNA).

### Claim 151 (depends on 1, 150)

The lipid particle of any of claims 1-150, wherein the lipid particle is pseudotyped with a viral envelope glycoprotein.

### Claim 152 (depends on 151)

The lipid particle of claim 151, wherein the viral envelope glycoprotein is a VSV-G protein or a functional variant thereof.

### Claim 153 (depends on 152)

The lipid particle of claim 152, wherein the VSV-G or a functional variant thereof comprises the amino acid sequence of SEQ ID NO: 199, or an amino acid sequence having at least 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% sequence identity to the amino acid sequence of SEQ ID NO: 199.

### Claim 154 (depends on 152, 153)

The lipid particle of claim 152 or claim 153, wherein the VSV-G or a functional variant thereof comprises the amino acid sequence of SEQ ID NO: 199.

### Claim 155 (depends on 151)

The lipid particle of claim 151, wherein the viral envelope glycoprotein is a Cocal virus G protein or a functional variant thereof.

### Claim 156 (depends on 151)

The lipid particle of claim 151, wherein the viral envelope glycoprotein is an Alphavirus fusion protein (e.g. Sindbis virus) or a functional variant thereof.

### Claim 157 (depends on 151)

The lipid particle of claim 151, wherein the viral envelope glycoprotein is a Paramyxoviridae fusion protein (e.g., a Morbillivirus or a Henipavirus) or a functional variant thereof.

### Claim 158 (depends on 151, 157)

The lipid particle of claim 151 or claim 157, wherein the viral envelope glycoprotein is a Morbillivirus fusion protein (e.g., measles virus (MeV), canine distemper virus, Cetacean morbillivirus, Peste-des-petits-ruminants virus, Phocine distemper virus, Rinderpest virus) or a functional variant thereof.

### Claim 159 (depends on 151, 157)

The lipid particle of claim 151 or claim 157, wherein the viral envelope glycoprotein is a Henipavirus fusion protein (e.g., Nipah virus, Hendra virus, Cedar virus, Kumasi virus, Mòjiāng virus, Langya virus) or a functional variant thereof.

### Claim 160 (depends on 151, 152, 153, 154, 155, 156, 157, 158, 159)

The lipid particle of any of claims 151-159, wherein the viral envelope glycoprotein comprises one or more modifications to reduce binding to its native receptor.

### Claim 161 (depends on 151, 157, 159)

The lipid particle of any of claims 151, 157, 159, and 160, wherein the viral envelope glycoprotein comprises a Nipah virus F glycoprotein (NiV-F) or a biologically active portion thereof and a Nipah virus G glycoprotein (NiV-G) or a biologically active portion thereof.

### Claim 162 (depends on 161)

The lipid particle of claim 161, wherein the Niv-F or a biologically active portion thereof comprises the amino acid sequence set forth in SEQ ID NO: 145, or an amino acid sequence having at least 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% sequence identity to the amino acid sequence set forth in SEQ ID NO: 145; and/or the Niv-G or a biologically active portion thereof comprises the amino acid sequence set forth in SEQ ID NO: 147, or an amino acid sequence having at least 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% sequence identity to the amino acid sequence set forth in SEQ ID NO: 147.

### Claim 163 (depends on 161)

The lipid particle of claim 161, wherein the Niv-F or a biologically active portion thereof comprises the amino acid sequence set forth in SEQ ID NO: 145; and/or the Niv-G or a biologically active portion thereof comprises the amino acid sequence set forth in SEQ ID NO: 147.

### Claim 164 (depends on 161)

The lipid particle of claim 161, wherein the NiV-G or the biologically active portion thereof is a wild-type NiV-G protein or a functionally active variant or biologically active portion thereof.

### Claim 165 (depends on 161, 164)

The lipid particle of claim 161 or claim 164, wherein the NiV-G protein or the biologically active portion is truncated and lacks up to 40 contiguous amino acid residues at or near the N-terminus of the wild-type NiV-G protein.

### Claim 166 (depends on 161, 162, 163, 164, 165)

The lipid particle of any of claims 161-165, wherein the NiV-G protein or the biologically active portion has a 5 amino acid truncation at or near the N-terminus of the wild-type NiV-G protein, optionally wherein the NiV-G protein or the biologically active portion thereof has the amino acid sequence set forth in SEQ ID NO: 12, or a sequence of amino acids that exhibits at least at or about 80%, 85%, 90% or 95% sequence identity to the sequence set forth in SEQ ID NO: 12.

### Claim 167 (depends on 161, 162, 163, 164, 165, 166)

The lipid particle of any of claims 161-166, wherein the NiV-G protein or the biologically active portion has a 10 amino acid truncation at or near the N-terminus of the wild-type NiV-G protein, optionally wherein the NiV-G protein or the biologically active portion thereof has the amino acid sequence set forth in SEQ ID NO:44, or a sequence of amino acids that exhibits at least at or about 80%, 85%, 90% or 95% sequence identity to the sequence set forth in SEQ ID NO: 44.

### Claim 168 (depends on 161, 162, 163, 164, 165, 166, 167)

The lipid particle of any of claims 161-167, wherein the NiV-G protein or the biologically active portion has a 15 amino acid truncation at or near the N-terminus of the wild-type NiV-G protein, optionally wherein the NiV-G protein or the biologically active portion thereof has the amino acid sequence set forth in SEQ ID NO:45, or a sequence of amino acids that exhibits at least at or about 80%, 85%, 90% or 95% sequence identity to the sequence set forth in SEQ ID NO: 45.

### Claim 169 (depends on 161, 162, 163, 164, 165, 166, 167, 168)

The lipid particle of any of claims 161-168, wherein the NiV-G protein or the biologically active portion has a 20 amino acid truncation at or near the N-terminus of the wild-type NiV-G protein, optionally wherein the NiV-G protein or the biologically active portion thereof has the amino acid sequence set forth in SEQ ID NO:13, or a sequence of amino acids that exhibits at least at or about 80%, 85%, 90% or 95% sequence identity to the sequence set forth in SEQ ID NO: 13.

### Claim 170 (depends on 161, 162, 163, 164, 165, 166, 167, 168)

The lipid particle of any of claims 161-168, wherein the NiV-G protein or the biologically active portion has a 25 amino acid truncation at or near the N-terminus of the wild-type NiV-G protein, optionally wherein the NiV-G protein or the biologically active portion thereof has the amino acid sequence set forth in SEQ ID NO: 14, or a sequence of amino acids that exhibits at least at or about 80%, 85%, 90% or 95% sequence identity to the sequence set forth in SEQ ID NO: 14.

### Claim 171 (depends on 161, 162, 163, 164, 165, 166, 167, 168)

The lipid particle of any of claims 161-168, wherein the NiV-G protein or the biologically active portion has a 30 amino acid truncation at or near the N-terminus of the wild-type NiV-G protein, optionally wherein the NiV-G protein or the biologically active portion thereof has the amino acid sequence set forth in SEQ ID NO:43, or a sequence of amino acids that exhibits at least at or about 80%, 85%, 90% or 95% sequence identity to the sequence set forth in SEQ ID NO: 43.

### Claim 172 (depends on 161, 162, 163, 164, 165, 166, 167, 168)

The lipid particle of any of claims 161-168, wherein the NiV-G protein or the biologically active portion has a 34 amino acid truncation at or near the N-terminus of the wild-type NiV-G protein, optionally wherein the NiV-G protein or the biologically active portion thereof has the amino acid sequence set forth in SEQ ID NO:42, or a sequence of amino acids that exhibits at least at or about 80%, 85%, 90% or 95% sequence identity to the sequence set forth in SEQ ID NO: 42.

### Claim 173 (depends on 161, 162, 163, 164, 165, 166, 167, 168, 169, 170, 171, 172)

The lipid particle of any of claims 161-172, wherein the NiV-G-protein or the biologically active portion thereof is a mutant NiV-G protein that exhibits reduced binding to Ephrin B2 or Ephrin B3.

### Claim 174 (depends on 173)

The lipid particle of claim 173, wherein the mutant NiV-G protein or the biologically active portion comprises one or more amino acid substitutions corresponding to amino acid substitutions selected from the group consisting of E501A, W504A, Q530A and E533A with reference to numbering set forth in SEQ ID NO:4.

### Claim 175 (depends on 173, 174)

The lipid particle of claim 173 or claim 174, wherein the mutant NiV-G protein or the biologically active portion comprises the amino acid sequence set forth in SEQ ID NO: 17 or a sequence of amino acids that exhibits at least at or about 80%, 85%, 90% or 95% sequence identity to the sequence set forth in SEQ ID NO: 17.

### Claim 176 (depends on 173, 174)

The lipid particle of claim 173 or claim 174, wherein the NiV-G protein or the biologically active portion has the amino acid sequence set forth in SEQ ID NO: 18 or a sequence of amino acids that exhibits at least at or about 80%, 85%, 90% or 95% sequence identity to the sequence set forth in SEQ ID NO: 18.

### Claim 177 (depends on 161, 162, 163, 164, 165, 166, 167, 168, 169, 170, 171, 172, 173, 174, 175, 176)

The lipid particle of any of claims 161-176, wherein the NiV-F protein or the biologically active portion thereof is a wild-type NiV-F protein or is a functionally active variant or a biologically active portion thereof.

### Claim 178 (depends on 161, 162, 163, 164, 165, 166, 167, 168, 169, 170, 171, 172, 173, 174, 175, 176, 177)

The lipid particle of any of claims 161-177, wherein the NiV-F protein or the biologically active portion thereof has a 20 amino acid truncation at or near the C-terminus of the wild-type NiV-F protein, optionally wherein the NiV-F protein or the biologically active portion thereof comprises the sequence set forth in SEQ ID NO: 20 or a sequence of amino acids that exhibits at least at or about 80%, 85%, 90% or 95% sequence identity to the sequence set forth in SEQ ID NO: 20.

### Claim 179 (depends on 161, 162, 163, 164, 165, 166, 167, 168, 169, 170, 171, 172, 173, 174, 175, 176, 177, 178)

The lipid particle of any of claims 161-178, wherein the NiV-F protein or the biologically active portion thereof comprises:
i) a 20 amino acid truncation at or near the C-terminus of the wild-type NiV-F protein; and
ii) a point mutation on an N-linked glycosylation site,
optionally wherein the NiV-F protein or the biologically active portion thereof comprises the sequence set forth in SEQ ID NO: 15, or a sequence of amino acids that exhibits at least at or about 80%, 85%, 90% or 95% sequence identity to the sequence set forth in SEQ ID NO: 15.

### Claim 180 (depends on 161, 162, 163, 164, 165, 166, 167, 168, 169, 170, 171, 172, 173, 174, 175, 176, 177, 178, 179)

The lipid particle of any of claims 161-179, wherein the NiV-F protein or the biologically active portion thereof has a 22 amino acid truncation at or near the C-terminus of the wild-type NiV-F protein, optionally wherein the NiV-F protein or the biologically active portion thereof comprises the sequence set forth in SEQ ID NO: 16, 19, or 21 or a sequence of amino acids that exhibits at least at or about 80%, 85%, 90% or 95% sequence identity to the sequence set forth in SEQ ID NO: 16, 19, or 21.

### Claim 181 (depends on 161, 162, 163, 164, 165, 166, 167, 168, 169, 170, 171, 172, 173, 174, 175, 176, 177, 180)

The lipid particle of any of claims 161-177 and 180, wherein the NiV-F protein or the biologically active portion thereof comprises the amino acid sequence set forth in SEQ ID NO:21, or a sequence of amino acids that exhibits at least at or about 80%, 85%, 90% or 95% sequence identity to the sequence set forth in SEQ ID NO:21.

### Claim 182 (depends on 161, 162, 163, 164, 165, 166, 167, 168, 169, 170, 171, 172, 173, 174, 175, 176, 177, 180)

The lipid particle of any of claims 161-177, 180, and 181, wherein the Niv-G protein comprises the amino acid sequence set forth in SEQ ID NO: 17, and the Niv-F protein comprises the amino acid sequence set forth in SEQ ID NO:21.

### Claim 183 (depends on 1, 182)

The lipid particle of any of claims 1-182, further comprising a targeting moiety.

### Claim 184 (depends on 183)

The lipid particle of claim 183, wherein the targeting moiety is selected from the group consisting of a CD3-binding agent, a CD8-binding agent, and a CD4-binding agent.

### Claim 185 (depends on 183, 184)

The lipid particle of claim 183 or claim 184, wherein the targeting moiety is a CD3-binding agent, optionally an anti-CD3 antibody or an antigen-binding fragment.

### Claim 186 (depends on 183, 184)

The lipid particle of claim 183 or claim 184, wherein the targeting moiety is a CD8-binding agent, optionally an anti-CD8 antibody or an antigen-binding fragment.

### Claim 187 (depends on 183, 184)

The lipid particle of claim 183 or claim 184, wherein the targeting moiety is a CD4-binding agent, optionally an anti-CD4 antibody or an antigen-binding fragment.

### Claim 188 (depends on 183, 184, 185, 186, 187)

The lipid particle of any of claims 183-187, wherein the targeting moiety is exposed on the surface of the lipid particle.

### Claim 189 (depends on 183, 184, 185, 186, 187, 188)

The lipid particle of any of claims 183-188, wherein the targeting moiety is fused to a transmembrane domain incorporated into the bilayer of the lipid particle.

### Claim 190 (depends on 1, 189)

The lipid particle of any of claims 1-189, wherein the lipid particle is a retroviral vector or a retroviral-like particle.

### Claim 191 (depends on 1, 190)

The lipid particle of any of claims 1-190, wherein the retroviral vector or the retroviral-like particle is replication-deficient.

### Claim 192 (depends on 1, 191)

The lipid particle of any of claims 1-191, where the lipid particle does not comprise reverse transcriptase or does not comprise reverse transcriptase activity.

### Claim 193 (depends on 1, 191)

The lipid particle of any of claims 1-191, where the lipid particle does not comprise a protein with reverse transcriptase activity.

### Claim 194 (depends on 192, 193)

The lipid particle of claim 192 or claim 193, wherein the lipid particle does not comprise reverse transcriptase.

### Claim 195 (depends on 192, 193)

The lipid particle of claim 192 or claim 193, wherein the lipid particle comprises non-functional reverse transcriptase, optionally wherein the reverse transcriptase is mutated.

### Claim 196 (depends on 190, 191, 192, 193, 194, 195)

The lipid particle of any of claims 190-195, wherein the retroviral vector or retroviral-like particle comprises a RNA that is a self-inactivating lentiviral vector genome.

### Claim 197 (depends on 191, 192, 193, 194, 195, 196)

The lipid particle of any of claims 191-196, wherein the retroviral vector or retroviral-like particle comprises a RNA comprising a 3′LTR, and the 3′ LTR does not comprise a functional U3 domain, optionally wherein the U3 domain comprises a deletion.

### Claim 198 (depends on 1, 197)

The lipid particle of any of claims 1-197, wherein the lipid particle is a retroviral particle, and the retroviral particle is a lentiviral particle.

### Claim 199 (depends on 1, 197)

The lipid particle of any of claims 1-197, wherein the lipid particle is a retrovirus-like particle (VLP).

### Claim 200 (depends on 1, 199)

The lipid particle of any of claims 1-199, wherein the lipid bilayer is derived from a host cell.

### Claim 201 (depends on 200)

The lipid particle of claim 200, wherein the host cell is selected from the group consisting of a CHO cell, a BHK cell, a MDCK cell, a C3H 10T1/2 cell, a FLY cell, a Psi-2 cell, a BOSC 23 cell, a PA317 cell, a WEHI cell, a COS cell, a BSC 1 cell, a BSC 40 cell, a BMT 10 cell, a VERO cell, a W138 cell, a MRC5 cell, a A549 cell, a HT1080 cell, a 293 cell, a 293T cell, a B-50 cell, a 3T3 cell, a NIH3T3 cell, a HepG2 cell, a Saos-2 cell, a Huh7 cell, a HeLa cell, a W163 cell, a 211 cell, and a 211A cell.

### Claim 202

A method of producing a lipid particle comprising a lipid bilayer enclosing a lumen and a viral ribonucleic acid (RNA), comprising:
(1) providing a host cell comprising (a) a nucleic acid sequence selected from the group consisting of: a 5′ long terminal repeat (5′ LTR); a psi packaging signal sequence; a gag start codon; a RNA sequence encoding a heterologous protein; a 3′ long terminal repeat (3′ LTR); or a combination thereof; and (b) a nucleic acid sequence encoding a protein selected from the group consisting of gag, pol, rev, tat, a viral envelope glycoprotein, or a combination thereof; and
(2) culturing the host cell under conditions to induce packaging of the lipid particle.

### Claim 203 (depends on 202)

The method of claim 202, further comprising a RNA sequence encoding a viral structural protein or a portion thereof, which is located between the gag start codon and the RNA sequence encoding a heterologous protein.

### Claim 204 (depends on 202)

The method of claim 202, wherein the gag start codon and the RNA sequence encoding a heterologous protein are part of the same RNA, and the RNA does not comprise nucleotides between the gag start codon and the RNA sequence encoding a heterologous protein.

### Claim 205

A method of producing a lipid particle comprising a lipid bilayer enclosing a lumen and viral ribonucleic acid (RNA), comprising:
(1) providing a host cell comprising (a) a RNA sequence encoding a heterologous protein and a viral structural protein or a portion thereof; and (b) a nucleic acid sequence encoding a protein selected from the group consisting of gag, pol, rev, tat, a viral envelope glycoprotein, or a combination thereof; and
(2) culturing the host cell under conditions to induce packaging of the lipid particle.

### Claim 206 (depends on 205)

The method of claim 205, wherein the RNA sequence encoding the viral structural protein or portion thereof is located 5′ to the RNA sequence encoding the heterologous protein.

### Claim 207 (depends on 203, 205)

The method of any of claims 203, 205, and 206, wherein a bicistronic element is located between the RNA sequence encoding the viral structural protein or portion thereof and the RNA sequence encoding the heterologous protein.

### Claim 208 (depends on 207)

The method of claim 207, wherein the bicistronic element is an internal ribosome entry site (IRES) element or a sequence encoding a 2A self-cleaving peptide.

### Claim 209 (depends on 207, 208)

The method of claim 207 or claim 208, wherein the bicistronic element is a sequence encoding a 2A self-cleaving peptide, and the 2A self-cleaving peptide is T2A.

### Claim 210 (depends on 209)

The method of claim 209, wherein T2A comprises the sequence set forth in SEQ ID NO: 76.

### Claim 211 (depends on 203, 205, 206, 207, 208, 209, 210)

The method of any of claims 203 and 205-210, wherein the RNA sequence encodes, from a 5′ to 3′ direction: the viral structural protein or portion thereof, T2A, and the heterologous protein.

### Claim 212 (depends on 203, 205, 206, 207, 208, 209, 210, 211)

The method of any of claims 203 and 205-211, wherein the viral structural protein is gag.

### Claim 213 (depends on 212)

The method of claim 212, wherein the RNA sequence encoding the viral structural protein or a portion thereof encodes an N-terminal portion of gag.

### Claim 214 (depends on 212, 213)

The method of claim 212 or claim 213, wherein the RNA sequence encoding the viral structural protein or a portion thereof comprises the sequence set forth in SEQ ID NO:52.

### Claim 215 (depends on 202, 203, 204, 205, 206, 207, 208, 209, 210, 211, 212, 213, 214)

The method of any of claims 202-214, wherein the host cell comprises a nucleic acid sequence that comprises the sequence set forth in SEQ ID NO:77 and encodes the heterologous protein.

### Claim 216

A method of producing a lipid particle comprising a lipid bilayer enclosing a lumen and a viral transfer plasmid, comprising
(1) providing a host cell comprising (a) a nucleic acid sequence encoding a fusion protein comprising a viral matrix (MA) protein and an RNA binding protein; (b) a nucleic acid sequence encoding a heterologous protein; and (c) a nucleic acid sequence encoding a protein selected from the group consisting of gag, pol, Rev, Tat, a viral envelope glycoprotein, or a combination thereof; and
(2) culturing the host cell under conditions to induce packaging of the lipid particle.

### Claim 217 (depends on 216)

The method of claim 216, wherein the RNA binding protein is a MS2 coat protein (MS2cp).

### Claim 218 (depends on 217)

The method of claim 217, wherein MS2cp comprises the sequence set forth in SEQ ID NO: 79.

### Claim 219 (depends on 216, 217, 218)

The method of any one of claims 216-218, wherein the nucleic acid sequence encoding a heterologous protein comprises a MS2cp-binding loop, optionally at or at least 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, or 24 MS2cp-binding loops.

### Claim 220 (depends on 219)

The method of claim 219, wherein the MS2cp-binding loop comprises the RNA sequence transcribed from the nucleic acid set forth in SEQ ID NO: 185 or SEQ ID NO: 174.

### Claim 221 (depends on 219, 220)

The method of claim 219 or claim 220, wherein the MS2cp-binding loop comprises the RNA sequence set forth in SEQ ID NO: 208.

### Claim 222 (depends on 216, 217, 218, 219, 220, 221)

The method of any one of claims 216-221, wherein the nucleic acid sequence encoding a heterologous protein comprises a plurality of MS2cp-binding loops, and wherein the plurality of MS2cp-binding loops comprises the RNA sequence transcribed from a nucleic acid sequence selected from the group consisting of SEQ ID NOs: 175-178.

### Claim 223 (depends on 216)

The method of claim 216, wherein the RNA binding protein is a lambda N protein (λN) or a functional variant thereof.

### Claim 224 (depends on 223)

The method of claim 223, wherein the λN or a functional variant thereof comprises the amino acid sequence of SEQ ID NO: 187 or an amino acid sequence having at least 90% or 95% sequence identity to the amino acid sequence of SEQ ID NO: 187.

### Claim 225 (depends on 223, 224)

The method of claim 223 or claim 224, wherein the λN or a functional variant thereof comprises the amino acid sequence of SEQ ID NO: 187.

### Claim 226 (depends on 223)

The method of claim 223, wherein the λN or a functional variant thereof comprises the amino acid sequence of SEQ ID NO: 188 or an amino acid sequence having at least 90% or 95% sequence identity to the amino acid sequence of SEQ ID NO: 188.

### Claim 227 (depends on 223, 226)

The method of claim 223 or claim 226, wherein the λN or a functional variant thereof comprises the amino acid sequence of SEQ ID NO: 188.

### Claim 228 (depends on 216, 223, 224, 225, 226, 227)

The method of any one of claims 216 and 223-227, wherein the nucleic acid sequence encoding a heterologous protein comprises a boxB binding site for binding to λN or a functional variant thereof, optionally at or at least 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, or 24 boxB binding sites.

### Claim 229 (depends on 228)

The method of claim 228, wherein the boxB binding site comprises the RNA sequence transcribed from the nucleic acid set forth in SEQ ID NO: 186.

### Claim 230 (depends on 216, 223, 224, 225, 226, 227, 228, 229)

The lipid particle of any one of claims 216 and 223-229, wherein the nucleic acid sequence encoding a heterologous protein comprises a plurality of boxB binding sites for binding to λN or a functional variant thereof, and the plurality of boxB binding sites comprises the RNA sequence transcribed from a nucleic acid sequence selected from the group consisting of SEQ ID NOs: 179-184.

### Claim 231

A method of producing a lipid particle comprising a lipid bilayer enclosing a lumen and a viral transfer plasmid, comprising:
(1) providing a host cell comprising (a) a nucleic acid sequence encoding a fusion protein comprising a viral matrix (MA) protein and a MS2 coat protein (MS2cp); (b) a nucleic acid sequence encoding a heterologous protein; and (c) a nucleic acid sequence encoding a protein selected from the group consisting of gag, pol, Rev, Tat, a viral envelope glycoprotein, or a combination thereof; and
(2) culturing the host cell under conditions to induce packaging of the lipid particle.

### Claim 232 (depends on 231)

The method of claim 231, wherein the fusion protein comprises, from a 5′ to 3′ direction: the viral MA protein and MS2cp.

### Claim 233 (depends on 231, 232)

The method of claim 231 or claim 232, wherein the nucleic acid sequence encoding a heterologous protein comprises a MS2cp-binding loop, optionally 12 or 24 MS2cp-binding loops.

### Claim 234 (depends on 231, 232, 233)

The method of any of claims 231-233, wherein the viral MA protein is derived from human immunodeficiency virus (HIV).

### Claim 235 (depends on 231, 232, 233, 234)

The method of any of claims 231-234, wherein the viral MA protein comprises the sequence set forth in SEQ ID NO:78.

### Claim 236 (depends on 231, 232, 233, 234, 235)

The method of any of claims 231-235, wherein MS2cp comprises the sequence set forth in SEQ ID NO:79.

### Claim 237 (depends on 231, 232, 233, 234, 235, 236)

The method of any of claims 231-236, wherein the fusion protein comprises the sequence set forth in SEQ ID NO:74.

### Claim 238

A method of producing a lipid particle comprising a lipid bilayer enclosing a lumen and a viral transfer plasmid, comprising:
(1) providing a host cell comprising (a) a nucleic acid sequence encoding a fusion protein comprising a viral envelope glycoprotein and an RNA binding protein; (b) a nucleic acid sequence encoding a heterologous protein; and
(2) culturing the host cell under conditions to induce packaging of the lipid particle.

### Claim 239 (depends on 238)

The method of claim 238, wherein the host cells further comprises a nucleic acid sequence encoding a protein selected from the group consisting of gag, pol, Rev, Tat, or a combination thereof.

### Claim 240 (depends on 238, 239)

The method of claim 238 or claim 239, wherein the fusion protein comprises, from a 5′ to 3′ direction: the viral envelope glycoprotein and the RNA binding protein.

### Claim 241 (depends on 238, 239, 240)

The method of any one of claims 238-240, wherein the viral envelope glycoprotein is a VSV-G protein or a functional variant thereof.

### Claim 242 (depends on 238, 239, 240, 241)

The method of any one of claims 238-241, wherein the RNA binding protein is a MS2 coat protein (MS2cp).

### Claim 243 (depends on 242)

The method of claim 242, wherein MS2cp comprises the sequence set forth in SEQ ID NO: 79.

### Claim 244 (depends on 238, 239, 240, 241, 242, 243)

The method of any one of claims 238-243, wherein the nucleic acid sequence encoding a heterologous protein comprises a MS2cp-binding loop, optionally at or at least 12 or 24 MS2cp-binding loops.

### Claim 245 (depends on 244)

The method of claim 244, wherein the MS2cp-binding loop comprises the RNA sequence transcribed from the nucleic acid set forth in SEQ ID NO: 185 or SEQ ID NO: 174.

### Claim 246 (depends on 244, 245)

The lipid particle of claim 244 or claim 245, wherein the MS2cp-binding loop comprises the RNA sequence set forth in SEQ ID NO: 208.

### Claim 247 (depends on 238, 239, 240, 241, 242, 243, 244, 245, 246)

The method of any one of claims 238-246, wherein the nucleic acid sequence encoding a heterologous protein comprises a plurality of MS2cp-binding loops, and wherein the plurality of MS2cp-binding loops comprises the RNA sequence transcribed from a nucleic acid sequence selected from the group consisting of SEQ ID NOs: 175-178.

### Claim 248 (depends on 238, 239, 240, 241, 242, 243, 244, 245, 246, 247)

The method of any of claims 238-247, wherein the viral envelope glycoprotein is derived from human immunodeficiency virus (HIV).

### Claim 249 (depends on 238, 239, 240, 241)

The method of any one of claims 238-241, wherein the RNA binding protein is a lambda N protein (λN) or a functional variant thereof.

### Claim 250 (depends on 238, 239, 240, 241, 249)

The method of any one of claims 238-241 and 249, wherein the nucleic acid sequence encoding a heterologous protein comprises a boxB binding site for binding to λN or a functional variant thereof, optionally at or at least 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, or 24 boxB binding sites.

### Claim 251 (depends on 250)

The method of claim 250, wherein the boxB binding site comprises the RNA sequence transcribed from the nucleic acid set forth in SEQ ID NO: 186.

### Claim 252 (depends on 238, 239, 240, 241, 250)

The lipid particle of any one of claims 238-241, 250, and 251, wherein the nucleic acid sequence encoding a heterologous protein comprises a plurality of boxB binding sites for binding to λN or a functional variant thereof, and the plurality of boxB binding sites comprises the RNA sequence transcribed from a nucleic acid sequence selected from the group consisting of SEQ ID NOs: 179-184.

### Claim 253

A method of producing a lipid particle comprising a lipid bilayer enclosing a lumen and a viral transfer plasmid, comprising:
(1) providing a host cell comprising (a) a nucleic acid sequence encoding a fusion protein comprising viral matrix (MA) protein and a heterologous protein; and (b) a nucleic acid sequence encoding a protein selected from the group consisting of gag, pol, Rev, Tat, a viral envelope glycoprotein, or a combination thereof; and
(2) culturing the host cell under conditions to induce packaging of the lipid particle.

### Claim 254 (depends on 253)

The method of claim 253, wherein the fusion protein comprises, from a 5′ to 3′ direction: the viral MA protein and the heterologous protein.

### Claim 255 (depends on 253, 254)

The method of claim 253 or claim 254, wherein the viral MA protein is derived from human immunodeficiency virus (HIV).

### Claim 256 (depends on 253, 254, 255)

The method of any of claims 253-255, wherein the viral MA protein comprises the sequence set forth in SEQ ID NO:78.

### Claim 257 (depends on 202, 203, 204, 205, 206, 207, 208, 209, 210, 211, 212, 213, 214, 215, 216, 217, 218, 219, 220, 221, 222, 223, 224, 225, 226, 227, 228, 229, 230, 231, 232, 233, 234, 235, 236, 237, 238, 239, 240, 241, 242, 243, 244, 245, 246, 247, 248, 249, 250, 251, 252, 253, 254, 255, 256)

The method of any of claims 202-256, wherein the viral envelope glycoprotein is VSV-G.

### Claim 258 (depends on 202, 203, 204, 205, 206, 207, 208, 209, 210, 211, 212, 213, 214, 215, 216, 217, 218, 219, 220, 221, 222, 223, 224, 225, 226, 227, 228, 229, 230, 231, 232, 233, 234, 235, 236, 237, 238, 239, 240, 241, 242, 243, 244, 245, 246, 247, 248, 249, 250, 251, 252, 253, 254, 255, 256, 257)

The method of any of claims 202-257, wherein the host cell is selected from the group consisting of a CHO cell, a BHK cell, a MDCK cell, a C3H 10T1/2 cell, a FLY cell, a Psi-2 cell, a BOSC 23 cell, a PA317 cell, a WEHI cell, a COS cell, a BSC 1 cell, a BSC 40 cell, a BMT 10 cell, a VERO cell, a W138 cell, a MRC5 cell, a A549 cell, a HT1080 cell, a 293 cell, a 293T cell, a B-50 cell, a 3T3 cell, a NIH3T3 cell, a HepG2 cell, a Saos-2 cell, a Huh7 cell, a HeLa cell, a W163 cell, a 211 cell, and a 211A cell.

### Claim 259 (depends on 202, 203, 204, 205, 206, 207, 208, 209, 210, 211, 212, 213, 214, 215, 216, 217, 218, 219, 220, 221, 222, 223, 224, 225, 226, 227, 228, 229, 230, 231, 232, 233, 234, 235, 236, 237, 238, 239, 240, 241, 242, 243, 244, 245, 246, 247, 248, 249, 250, 251, 252, 253, 254, 255, 256, 257, 258)

The method of any of claims 202-258, wherein the nucleic acid sequence in (b) comprises a 5′ promoter.

### Claim 260 (depends on 231, 232, 233, 234, 235, 236, 237, 238, 239, 240, 241, 242, 243, 244, 245, 246, 247, 248, 249, 250, 251, 252, 253, 254, 255, 256, 257, 258, 259)

The method of any of claims 231-259, wherein the nucleic acid sequence in (c) comprises a 5′ promoter.

### Claim 261 (depends on 259, 260)

The method of claim 259 or claim 260, wherein the promoter is a cytomegalovirus (CMV) promoter.

### Claim 262 (depends on 202, 203, 204, 205, 206, 207, 208, 209, 210, 211, 212, 213, 214, 215, 216, 217, 218, 219, 220, 221, 222, 223, 224, 225, 226, 227, 228, 229, 230, 231, 232, 233, 234, 235, 236, 237, 238, 239, 240, 241, 242, 243, 244, 245, 246, 247, 248, 249, 250, 251, 252, 253, 254, 255, 256, 257, 258, 259, 260, 261)

A lipid particle produced by the methods of any of claims 202-261.

### Claim 263 (depends on 1, 201, 262)

A composition comprising the lipid particle of any of claims 1-201 and 262.

### Claim 264 (depends on 1, 201, 262, 263)

A method of introducing a heterologous protein into a target cell, the method comprising contacting the target cell with the lipid particle of any of claims 1-201 and 262 or the composition of claim 263.

### Claim 265 (depends on 1, 201, 262, 263)

A method of genetically engineering a target cell, the method comprising contacting the target cell with the lipid particle of any of claims 1-201 and 262 or the composition of claim 263.

### Claim 266 (depends on 264, 265)

The method of claim 264 or claim 265, wherein the contacting is in vitro or ex vivo.

### Claim 267 (depends on 264, 265)

The method of claim 264 or claim 265, wherein the contacting is in vivo.

### Claim 268

A deoxyribonucleic acid (DNA) sequence encoding a gag start codon and a heterologous protein.

### Claim 269 (depends on 268)

The DNA sequence of claim 268, further encoding a viral structural protein or a portion thereof, wherein the portion of the DNA sequence encoding the viral structural protein is located between the portions of the DNA sequence encoding the gag start codon and the heterologous protein.

### Claim 270 (depends on 268, 269)

The DNA sequence of claim 268 or 269, further encoding a bicistronic element, wherein the portion of the DNA sequence encoding the bicistronic element is located between the portions of the DNA sequence encoding the viral structural protein or a portion thereof and the heterologous protein.

### Claim 271 (depends on 270)

The DNA sequence of claim 270, wherein the bicistronic element is an internal ribosome entry site (IRES) element or a sequence encoding a 2A self-cleaving peptide.

### Claim 272 (depends on 271)

The DNA sequence of claim 271, wherein the 2A self-cleaving peptide is T2A.

### Claim 273 (depends on 272)

The DNA sequence of claim 272, wherein T2A comprises the sequence set forth in SEQ ID NO: 76.

### Claim 274 (depends on 269, 270, 271, 272, 273)

The DNA sequence of any of claims 269-273, wherein the DNA sequence encodes from a 5′ to 3′ direction: the viral structural protein or portion thereof, T2A, and the heterologous protein.

### Claim 275 (depends on 269, 270, 271, 272, 273, 274)

The DNA sequence of any of claims 269-274, wherein the viral structural protein is gag.

### Claim 276 (depends on 275)

The DNA sequence of claim 275, encoding an N-terminal portion of gag.

### Claim 277 (depends on 275, 276)

The DNA sequence of claim 275 or claim 276, wherein the N-terminal portion of gag comprises the sequence set forth in SEQ ID NO:52.

### Claim 278 (depends on 268, 269, 270, 271, 272, 273, 274, 275, 276, 277)

The DNA sequence of any of claims 268-277, which encodes the sequence set forth in SEQ ID NO:77 and the heterologous protein.

### Claim 279 (depends on 278)

The DNA sequence of claim 278, which does not comprise nucleotides between the encoded gag start codon and the encoded heterologous protein.

### Claim 280 (depends on 268, 269, 270, 271, 272, 273, 274, 275, 276, 277, 278, 279)

The DNA sequence of any of claims 268-279, comprising a promoter.

### Claim 281 (depends on 280)

The DNA sequence of claim 280, wherein the promoter is a cytomegalovirus (CMV) promoter.

### Claim 282

A DNA sequence encoding a viral matrix (MA) protein, an RNA binding protein, and a cleavage site between the portions of the DNA sequence encoding the MA protein and the RNA binding protein.

### Claim 283 (depends on 282)

The DNA sequence of claim 282, which encodes a fusion protein comprising, from 5′ to 3′, the viral MA protein and RNA binding protein.

### Claim 284 (depends on 282, 283)

The DNA sequence of claim 282 or claim 283, wherein the RNA binding protein is a MS2 coat protein (MS2cp).

### Claim 285 (depends on 284)

The DNA sequence of claim 284, wherein MS2cp comprises the sequence set forth in SEQ ID NO:79.

### Claim 286 (depends on 282, 283)

The DNA sequence of claim 282 or claim 283, wherein the RNA binding protein is a lambda N protein (λN) or a functional variant thereof.

### Claim 287 (depends on 286)

The DNA sequence of claim 286, wherein the λN or a functional variant thereof comprises the amino acid sequence of SEQ ID NO: 187 or 188.

### Claim 288 (depends on 282, 283, 284, 285, 286, 287)

The DNA sequence of any of claims 282-287 wherein the encoded viral MA protein comprises the sequence set forth in SEQ ID NO:78.

### Claim 289 (depends on 282, 283, 284, 285, 286, 287, 288)

The DNA sequence of any one of claims 282-288, comprising the nucleic acid sequence set forth in any one of SEQ ID NOs: 62, 150, 153, and 154.

### Claim 290

A DNA sequence encoding a viral matrix (MA) protein, a MS2 coat protein (MS2cp), and a cleavage site between the portions of the DNA sequence encoding the MA protein and the MS2cp.

### Claim 291 (depends on 290)

The DNA sequence of claim 290, which encodes a fusion protein comprising, from 5′ to 3′, the viral MA protein and MS2cp.

### Claim 292 (depends on 290, 291)

The DNA sequence polynucleotide of claim 290 or claim 291, wherein the encoded MS2cp comprises a MS2cp-binding loop, optionally 12 or 24 MS2cp-binding loops.

### Claim 293 (depends on 290, 291, 292)

The DNA sequence of any of claims 290-292, wherein the encoded viral MA protein is derived from human immunodeficiency virus (HIV).

### Claim 294 (depends on 290, 291, 292, 293)

The DNA sequence of any of claims 290-293, wherein the encoded viral MA protein comprises the sequence set forth in SEQ ID NO:78.

### Claim 295 (depends on 290, 291, 292, 293, 294)

The DNA sequence of any of claims 290-294, wherein the encoded MS2cp comprises the sequence set forth in SEQ ID NO:79.

### Claim 296 (depends on 290, 291, 292, 293, 294, 295)

The DNA sequence of any of claims 290-295, wherein the encoded fusion protein comprises the sequence set forth in SEQ ID NO:74.

### Claim 297

A DNA sequence encoding a viral envelope glycoprotein, an RNA binding protein, and a cleavage site between the portions of the DNA sequence encoding the viral envelope glycoprotein and the RNA binding protein.

### Claim 298 (depends on 297)

The DNA sequence of claim 297, wherein the fusion protein comprises, from a 5′ to 3′ direction: the viral envelope glycoprotein and the RNA binding protein.

### Claim 299 (depends on 297, 298)

The DNA sequence of claim 297 or claim 298, wherein the viral envelope glycoprotein is a VSV-G protein or a functional variant thereof.

### Claim 300 (depends on 297, 298, 299)

The DNA sequence of any of claims 297-299, wherein the viral envelope glycoprotein is derived from human immunodeficiency virus (HIV).

### Claim 301 (depends on 297, 298, 299, 300)

The DNA sequence of any one of claims 297-300, wherein the RNA binding protein is a MS2 coat protein (MS2cp).

### Claim 302 (depends on 301)

The DNA sequence of claim 301, wherein MS2cp comprises the sequence set forth in SEQ ID NO:79.

### Claim 303 (depends on 297, 298, 299, 300)

The DNA sequence of any one of claims 297-300, wherein the RNA binding protein is a lambda N protein (λN) or a functional variant thereof.

### Claim 304 (depends on 303)

The DNA sequence of claim 303, wherein the λN or a functional variant thereof comprises the amino acid sequence set forth in SEQ ID NO: 187 or 188.

### Claim 305 (depends on 297, 298)

The DNA sequence of claim 297 or claim 298, comprising a nucleic acid sequence selected from the group consisting of SEQ ID NOs: 62 and 150-156.

### Claim 306 (depends on 297, 298, 299, 300, 301, 302)

The DNA sequence of any one of claims 297-302, comprising the nucleic acid sequence set forth in SEQ ID NO: 151 or 152.

### Claim 307 (depends on 297, 298, 299, 300, 301, 302)

The DNA sequence of any one of claims 297-302, comprising a nucleic acid sequence encoding the amino acid sequence set forth in SEQ ID NO: 157 or 158.

### Claim 308 (depends on 297, 298, 299, 300, 301, 302)

The DNA sequence of any one of claims 297-302, comprising a nucleic acid sequence encoding the amino acid sequence set forth in SEQ ID NO: 192 or 193.

### Claim 309 (depends on 297, 298, 299, 300, 303)

The DNA sequence of any one of claims 297-300, 303, and 304, comprising the nucleic acid sequence set forth in SEQ ID NO: 155 or 156.

### Claim 310 (depends on 297, 298, 299, 300, 303, 304)

The DNA sequence of any one of claims 297-300, 303, 304, and 309, comprising a nucleic acid sequence encoding the amino acid sequence set forth in SEQ ID NO: 161 or 162.

### Claim 311 (depends on 297, 298, 299, 300, 303, 304)

The DNA sequence of any one of claims 297-300, 303, 304, and 309, comprising a nucleic acid sequence encoding the amino acid sequence set forth in SEQ ID NO: 196 or 197.312.A DNA sequence encoding a viral matrix (MA) protein and a heterologous protein.

### Claim 313 (depends on 312)

The DNA sequence of claim 312, which encodes a fusion protein comprising, from 5′ to 3′, the viral MA protein and the heterologous protein.

### Claim 314 (depends on 312, 313)

The DNA sequence of claim 312 or claim 313, wherein the encoded viral MA protein is derived from human immunodeficiency virus (HIV).

### Claim 315 (depends on 312, 313, 314)

The DNA sequence of any of claims 312-314, wherein the encoded viral MA protein comprises the sequence set forth in SEQ ID NO:78.

### Claim 316 (depends on 1, 201, 202, 203, 204, 205, 206, 207, 208, 209, 210, 211, 212, 213, 214, 215, 216, 217, 218, 219, 220, 221, 222, 223, 224, 225, 226, 227, 228, 229, 230, 231, 232, 233, 234, 235, 236, 237, 238, 239, 240, 241, 242, 243, 244, 245, 246, 247, 248, 249, 250, 251, 252, 253, 254, 255, 256, 257, 258, 259, 260, 261, 262, 263, 264, 265, 266, 267, 268, 269, 270, 271, 272, 273, 274, 275, 276, 277, 278, 279, 280, 281, 312, 313, 314, 315)

The lipid particle of any of claims 1-201 and 262, the composition of claim 263, the method of any of claims 202-261 and 264-267, or the DNA sequence of any of claims 268-281 and 312-315, wherein the heterologous protein is a genome-modifying protein.

### Claim 317 (depends on 316)

The lipid particle, composition, method, or DNA sequence of claim 316, wherein the genome-modifying protein comprises a recombinant nuclease, a nickase, an integrase, reverse transcriptase, or a combination thereof.

### Claim 318 (depends on 316, 317)

The lipid particle, composition, method, or DNA sequence of claim 316 or claim 317, wherein the genome-modifying protein comprises a zinc-finger nuclease (ZFN), a transcription-activator like effector nucleases (TALEN), or a CRISPR-associated (Cas) protein.

### Claim 319 (depends on 316, 317, 318)

The lipid particle, composition, method, or DNA sequence of any of claims 316-318, wherein the genome-modifying protein is a Cas protein.

### Claim 320 (depends on 316, 317, 318, 319)

The lipid particle, composition, method, or DNA sequence of any of claims 316-319, wherein the genome-modifying protein is (i) Cas9, optionally saCas9 or spCas9; or (ii) cpf1.

### Claim 321 (depends on 1, 201, 202, 203, 204, 205, 206, 207, 208, 209, 210, 211, 212, 213, 214, 215, 216, 217, 218, 219, 220, 221, 222, 223, 224, 225, 226, 227, 228, 229, 230, 231, 232, 233, 234, 235, 236, 237, 238, 239, 240, 241, 242, 243, 244, 245, 246, 247, 248, 249, 250, 251, 252, 253, 254, 255, 256, 257, 258, 259, 260, 261, 262, 263, 264, 265, 266, 267, 268, 269, 270, 271, 272, 273, 274, 275, 276, 277, 278, 279, 280, 281, 312, 313, 314, 315)

The lipid particle of any of claims 1-201 and 262, the composition of claim 263, the method of any of claims 202-261 and 264-267, or the DNA sequence of any of claims 268-281 and 312-315, wherein the heterologous protein is a tumor neoepitope.

### Claim 322 (depends on 1, 201, 202, 203, 204, 205, 206, 207, 208, 209, 210, 211, 212, 213, 214, 215, 216, 217, 218, 219, 220, 221, 222, 223, 224, 225, 226, 227, 228, 229, 230, 231, 232, 233, 234, 235, 236, 237, 238, 239, 240, 241, 242, 243, 244, 245, 246, 247, 248, 249, 250, 251, 252, 253, 254, 255, 256, 257, 258, 259, 260, 261, 262, 263, 264, 265, 266, 267, 268, 269, 270, 271, 272, 273, 274, 275, 276, 277, 278, 279, 280, 281, 312, 313, 314, 315)

The lipid particle of any of claims 1-201 and 262, the composition of claim 263, the method of any of claims 202-261 and 264-267, or the DNA sequence of any of claims 268-281 and 312-315, wherein the heterologous protein is a viral Spike(s) glycoprotein.

### Claim 323 (depends on 1, 201, 202, 203, 204, 205, 206, 207, 208, 209, 210, 211, 212, 213, 214, 215, 216, 217, 218, 219, 220, 221, 222, 223, 224, 225, 226, 227, 228, 229, 230, 231, 232, 233, 234, 235, 236, 237, 238, 239, 240, 241, 242, 243, 244, 245, 246, 247, 248, 249, 250, 251, 252, 253, 254, 255, 256, 257, 258, 259, 260, 261, 262, 263, 264, 265, 266, 267, 268, 269, 270, 271, 272, 273, 274, 275, 276, 277, 278, 279, 280, 281, 312, 313, 314, 315)

The lipid particle of any of claims 1-201 and 262, the composition of claim 263, the method of any of claims 202-261 and 264-267, or the DNA sequence of any of claims 268-281 and 312-315, wherein the heterologous protein is a protein from Zika virus, optionally Zika virus prM-E protein; tuberculosis; respiratory syncytial virus (RSV), optionally RSV fusion (RSV-F) protein; influenza virus, optionally influenza virus hemagglutinin (HA); rabies virus, optionally rabies virus glycoprotein (RABV-G); human cytolomegalovirus (CMV); hepatitis C virus; human immunodeficiency virus 1 (HIV-1), and Streptococcus.

### Claim 324 (depends on 1, 201, 202, 203, 204, 205, 206, 207, 208, 209, 210, 211, 212, 213, 214, 215, 216, 217, 218, 219, 220, 221, 222, 223, 224, 225, 226, 227, 228, 229, 230, 231, 232, 233, 234, 235, 236, 237, 238, 239, 240, 241, 242, 243, 244, 245, 246, 247, 248, 249, 250, 251, 252, 253, 254, 255, 256, 257, 258, 259, 260, 261, 262, 263, 264, 265, 266, 267, 268, 269, 270, 271, 272, 273, 274, 275, 276, 277, 278, 279, 280, 281, 312, 313, 314, 315)

The lipid particle of any of claims 1-201 and 262, the composition of claim 263, the method of any of claims 202-261 and 264-267, or the DNA sequence of any of claims 268-281 and 312-315, wherein the heterologous protein is an antibody or an antigen-binding fragment thereof.

### Claim 325 (depends on 268, 269, 270, 271, 272, 273, 274, 275, 276, 277, 278, 279, 280, 281, 282, 283, 284, 285, 286, 287, 288, 289, 290, 291, 292, 293, 294, 295, 296, 297, 298, 299, 300, 301, 302, 303, 304, 305, 306, 307, 308, 309, 310, 311, 312, 313, 314, 315, 316, 317, 318, 319, 320, 321, 322, 323, 324)

A vector comprising the DNA sequence of any of claims 268-324.

### Claim 326 (depends on 268, 269, 270, 271, 272, 273, 274, 275, 276, 277, 278, 279, 280, 281, 282, 283, 284, 285, 286, 287, 288, 289, 290, 291, 292, 293, 294, 295, 296, 297, 298, 299, 300, 301, 302, 303, 304, 305, 306, 307, 308, 309, 310, 311, 312, 313, 314, 315, 316, 317, 318, 319, 320, 321, 322, 323, 324, 325)

A mammalian cell comprising the DNA sequence of any of claims 268-324 or the vector of claim 325.

### Claim 327 (depends on 326)

The mammalian cell of claim 326, further comprising viral nucleic acid, wherein the viral nucleic acid lacks one or more genes involved in viral replication.

### Claim 328 (depends on 327)

The mammalian cell of claim 327, wherein the viral nucleic acid comprises:
one or more of (e.g., all of) the following nucleic acid sequences: 5′ LTR (e.g., comprising U5 and lacking a functional U3 domain), Psi packaging element (Psi), Central polypurine tract (cPPT)/central termination sequence (CTS) (e.g. DNA flap), Poly A tail sequence, a posttranscriptional regulatory element (e.g. WPRE), a Rev response element (RRE), and 3′ LTR (e.g., comprising U5 and lacking a functional U3);
a nucleic acid encoding a viral envelope protein; and/or
a nucleic acid encoding a viral packaging protein selected from one or more of gag, pol, rev and tat.

### Claim 329 (depends on 326, 327, 328)

The mammalian cell of any of claims 326-328, further comprising a RNA sequence encoding a heterologous protein.

### Claim 330 (depends on 326, 327, 328, 329)

The mammalian cell of any of claims 326-329, further comprising a guide RNA (gRNA).

### Claim 331

A transfer plasmid comprising a promoter operably linked to a RNA sequence encoding a gag protein or portion thereof comprising at least a gag start codon; a RNA sequence encoding a heterologous protein that is linked to the RNA sequence encoding a gag protein or portion thereof; and a 3′ long terminal repeat (3′ LTR).

### Claim 332

A transfer plasmid comprising a promoter operably linked to a ribonucleic acid (RNA), wherein the RNA comprises, from 5′ to 3′: a 5′ long terminal repeat (5′ LTR); a gag 5′ untranslated region (UTR) or portion thereof comprising at least three nucleotides; a RNA sequence encoding a heterologous protein that is linked to the gag 5′ UTR or a portion thereof; and a 3′ long terminal repeat (3′ LTR).

### Claim 333

A transfer plasmid comprising a promoter operably linked to a ribonucleic acid (RNA), wherein the RNA comprises, from 5′ to 3′: a 5′ long terminal repeat (5′ LTR); a retroviral packaging sequence; a gag start codon; a RNA sequence encoding a heterologous protein; and a 3′ long terminal repeat (3′ LTR).

### Claim 334 (depends on 333)

The transfer plasmid of claim 333, wherein the retroviral packaging sequence comprises a mutation in a major splice donor site.

### Claim 335 (depends on 334)

The transfer plasmid of claim 334, wherein the major splice donor site is a major splice donor site contained in SL2 of HIV psi.

### Claim 336 (depends on 334, 335)

The transfer plasmid of claim 334 or claim 335, wherein the mutation is a mutation that inhibits splicing at the major splice donor site.

### Claim 337 (depends on 334, 335, 336)

The transfer plasmid of any one of claims 334-336, wherein the mutated major splice donor site comprises a mutation that prevents splicing at the major splice donor site.

### Claim 338

A transfer plasmid comprising a promoter operably linked to a nucleic acid sequence encoding a fusion protein comprising a viral matrix (MA) protein and a MS2 coat protein (MS2cp).

### Claim 339

A transfer plasmid comprising a promoter operably linked to a nucleic acid sequence encoding a viral matrix (MA) protein and a heterologous protein.

### Claim 340 (depends on 331, 332, 333, 334, 335, 336, 337)

The transfer plasmid of any of claims 331-337, wherein the transfer plasmid is a lentiviral transfer plasmid.
